Marqueurs biologiques du diabète : apports et discordances des nouvelles technologies. À propos d’un cas clinique (notice n° 275484)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04382cam a2200421 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250117193348.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Mialon, Florian |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Marqueurs biologiques du diabète : apports et discordances des nouvelles technologies. À propos d’un cas clinique |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 60 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméDes discordances potentielles sont observées par les praticiens de diabétologie chez certains patients entre les marqueurs « classiques » du diabète (hémoglobine A1c, HbA1c) et les « nouveaux » marqueurs issus du monitorage continu du glucose (CGM, Continuous Glucose Monitoring). Les dispositifs de CGM donnent une HbA1c estimée ou eA1c, calculée selon la glycémie interstitielle moyenne et corrélée au temps relatif passé dans la cible glycémique ou Time-in-Range (TIR, %). Nous rapportons, à travers un cas clinique, l’existence de discordances et explorons leurs causes potentielles. L’eA1c est rendue sur la base des données recueillies par un capteur dont la durée de vie est de 14 jours, et l’HbA1c est un reflet rétrospectif sur 8 à 12 semaines de l’exposition à l’hyperglycémie. La patiente présentait un mauvais contrôle glycémique, se traduisant par une eA1c à 9 % contre une HbA1c dosée à 7,4 % et 7,7 % respectivement en immuno-dosage délocalisé (Siemens DCA- Vantage®) et en HPLC (Variant II Turbo). En plus des données du CGM, le déséquilibre glycémique et son caractère récent ont pu être objectivés par une fraction labile de l’HbA1c (LA1c) augmentée en HPLC. Ainsi, des variations récentes et/ou importantes du contrôle glycémique vont creuser un écart entre l’HbA1c et l’eA1c, pouvant induire des décisions thérapeutiques erronées. La nature différente des marqueurs les rend difficilement comparables en particulier en termes de durée de mesure. Ces dispositifs de lecture du glucose interstitiel en continu sont largement utilisés, il est important de comprendre et maîtriser les données qu’ils fournissent. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Potential discrepancies between laboratory and estimated (from Continuous Glucose Monitoring (CGM)) glycated hemoglobin (HbA1c) have been reported by diabetologists. CGM devices produce an eA1c derived from average glucose and correlated with Time-in-Range (TIR, %) which is the relative time spent in a range of normal glycaemia. Through a case report, we studied the potential causes for these discrepancies. CGM devices estimate eA1c during the lifespan of the sensor, that is replaced every 14 days and HbA1c is a retrospective data of exposure to hyperglycemia over 8 to 12 weeks. In our case report, the patient had a poor glycemic control resulting in 9% eA1c compared to 7,4% HbA1c got by delocalized immune-assay (Siemens DCA-Vantage®), confirmed at 7,7% by HPLC (Variant II Turbo). On top of the CGM data, an increased labile A1c (LA1c) fraction was found on the patient's HbA1c HPLC profile, both in favor of a recently altered glycemic control. Thus, recent and/or substantial variations in glycemic control will increase the gap between HbA1c and eA1c, being a potential source of therapeutic errors. The differences of those markers, particularly the time window during which it is estimated, make them hardly comparable. As the use of CGM is becoming widespread, it is important to understand and harness its data and biomarkers. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | A1c estimée |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | diabète |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biologie délocalisée |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lecteur de glucose |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | HPLC |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | continuous glucose monitoring |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | HbA1c |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | estimated A1c |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | HbA1c |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | point-of-care testing |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | diabetes |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | HPLC |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | continuous glucose monitoring |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | glucose monitor |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Catargi, Bogdan |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rami, Lila |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Barat, Pascal |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bedel, Aurélie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lacape, Geneviève |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bérard, Annie M. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Beauvieux, Marie-Christine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Annales de Biologie Clinique | 79 | 5 | 2021-09-01 | p. 445-451 | 0003-3898 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-annales-de-biologie-clinique-2021-5-page-445?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-annales-de-biologie-clinique-2021-5-page-445?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux